RPG Life Sciences Ltd Stock Price Today (NSE: RPGLIFE)

RPG Life Sciences Ltd

2302.00+13.30 (+0.58%)
Market Open

Fundamental Score

...

RPG Life Sciences Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

RPG Life Sciences Ltd share price today is 2302.00, up +0.58% on NSE/BSE as of 17 June 2026. RPG Life Sciences Ltd (RPGLIFE) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 3.68K (Cr). The 52-week high for RPGLIFE share price is 2725.00 and the 52-week low is 1733.00. At a P/E ratio of 33.04x, RPGLIFE is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 25.53% and a debt-to-equity ratio of 0.00.

RPG Life Sciences Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
2524.90
Low
2003.70
Volume
99.0K
Change
+10.98%

RPG Life Sciences Ltd share price chart: 10.98% return over the past month. 52-week high ₹2725.00, 52-week low ₹1733.00.

RPG Life Sciences Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
2183.502232.002170.002192.704.85K (Cr)
2224.002224.002163.302172.403.36K (Cr)
2235.102258.802187.202224.7012.04K (Cr)
2221.002246.002200.002232.6010.59K (Cr)
2253.702300.702205.002213.705.79K (Cr)
2308.002327.902243.002253.7010.26K (Cr)
2274.202329.002253.602293.905.92K (Cr)
2300.002330.902269.902274.203.76K (Cr)
2285.802355.002285.002300.0010.01K (Cr)
2273.002332.002273.002282.604.49K (Cr)

RPG Life Sciences Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
2224.002232.002163.302192.70-1.41%
2314.002524.902187.202224.70-3.86%
1941.102336.601840.402295.00+18.23%
1764.701985.001733.001857.70+5.27%
1981.002093.801864.001874.40-5.38%
2322.302357.901880.002007.90-13.54%
2297.402392.202175.002322.30+1.08%
2413.502480.002196.002278.10-5.61%
2234.202483.802210.802403.90+7.60%
2302.102463.202225.002234.20-2.95%
2385.102401.402247.502320.50-2.71%
2530.002725.002197.502401.00-5.10%

Returns & Performance

Excellent

Return on Equity (ROE)

25.53%

Profit generated per ₹1 of shareholder equity

Excellent

Return on Capital (ROCE)

32.80%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

21.43%

Average operating profit margin over 5 years

Dividend Yield

0.90%

Annual dividend as % of current share price

RPG Life Sciences Ltd Valuation Check

Poor

Price to Earnings (P/E)

33.04x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

72.95%

% shares held by company founders/management

Poor

FII Holding

1.11%

% shares held by foreign institutional investors

Average

DII Holding

6.70%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

38.23%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

5.50%

Revenue growth vs same quarter last year

Good

Revenue Growth (5-Year CAGR)

11.71%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

28.54%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

28.54%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.00x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

265.64x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

325.36 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

RPG Life Sciences Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of RPGLIFE across key market metrics for learning purposes.

Positive Indicators

11 factors identified

Strong Return on Equity (25.53%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (32.80%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Strong Operating Margins (21.43%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Robust Profit Growth (38.23%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Excellent EPS Growth (28.54% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (28.54% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Debt-Free Balance Sheet (D/E: 0.00)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (265.64x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Strong Cash Generation (₹325.36 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Balanced Promoter Holding (72.95%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

1 factors identified

Limited Institutional Interest (FII+DII: 7.81%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

RPG Life Sciences Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare RPG Life Sciences Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
62/100
2302
₹3682.76
33.0
Average
25.53%
Excellent
32.80%
Excellent
0.0
Excellent
28.54%
Excellent
11.71%
Good
0.90%
65.2/100
1844
₹433738.68
37.6
Average
16.86%
Good
20.21%
Excellent
0.1
Excellent
23.78%
Excellent
9.87%
Good
0.89%
67.9/100
6798
₹170445.88
68.6
Average
15.35%
Good
20.44%
Excellent
0.0
Excellent
10.41%
Good
11.65%
Good
0.47%
65.3/100
4538
₹126430.62
58.4
Average
26.52%
Excellent
27.05%
Excellent
0.3
Excellent
13.84%
Good
7.72%
Good
0.86%
Cipla Ltd...
CIPLA500087
59/100
1418
₹123059.76
22.6
Average
17.77%
Good
22.72%
Excellent
0.0
Excellent
28.68%
Excellent
9.97%
Good
0.85%
59.2/100
1319
₹105224.96
18.2
Average
17.96%
Good
22.69%
Excellent
0.2
Excellent
22.28%
Excellent
13.26%
Good
0.63%
Lupin Ltd...
LUPIN500257
66.7/100
2276
₹95148.15
22.0
Average
20.62%
Excellent
21.30%
Excellent
0.3
Excellent
54.88%
Excellent
8.11%
Good
0.58%
68.7/100
957
₹94253.78
18.7
Average
21.21%
Excellent
24.31%
Excellent
0.4
Excellent
25.92%
Excellent
10.27%
Good
1.17%
50.6/100
2420
₹92012.53
52.6
Average
14.68%
Average
15.98%
Good
0.6
Good
11.73%
Good
15.79%
Excellent
0.04%
28.8/100
1436
₹70798.69
20.7
Average
11.08%
Average
14.18%
Average
0.2
Excellent
3.87%
Average
6.55%
Good
0.33%
59.5/100
5452
₹67075.29
28.5
Average
19.39%
Good
20.38%
Excellent
0.2
Excellent
13.93%
Good
9.21%
Good
0.80%

RPG Life Sciences Ltd PE Ratio History

Historical price-to-earnings ratio for RPGLIFE — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 2025110.80₹2322.3021x
FY 202453.01₹2184.4541.2x
FY 202340.90₹1335.8532.7x
FY 202231.13₹847.0527.2x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

RPG Life Sciences Ltd Dividend History

Annual cash dividends paid by RPGLIFE — dividend yield 0.90%

Financial YearDividends Paid (₹ Cr)
FY 202526.46 Cr
FY 202419.85 Cr
FY 202315.88 Cr
FY 202211.91 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

RPG Life Sciences Ltd Quarterly Performance

Latest quarterly metrics for RPGLIFE — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

5.50%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

38.23%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

11.71%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

28.54%

Compounded annual net profit growth over 5 years

RPG Life Sciences Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for RPGLIFE — calculated from daily price history

22RSI 14
Oversold — RSI 22

Selling pressure is heavy — potential reversal zone.

SMA 50
2074
▲ Price above SMA 50 — Short-term bullish
SMA 200
2201
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
79K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

RPG Life Sciences Ltd Financial Statements

Annual income statement, balance sheet and cash flow for RPG Life Sciences Ltd (RPGLIFE) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for RPG Life Sciences Ltd

About RPGLIFE (RPG Life Sciences Ltd)

RPG Life Sciences Ltd is a dynamic pharmaceutical entity operating on both Indian and global stages. The company's core business revolves around the creation, production, and distr...ibution of a wide array of pharmaceutical products. These include branded formulations targeting specific therapeutic needs, cost-effective generic medications ensuring wider accessibility, and the fundamental building blocks of many drugs – synthetic Active Pharmaceutical Ingredients (APIs). With a robust infrastructure and a focus on scientific advancement, RPG Life Sciences is committed to delivering high-quality healthcare solutions. Their efforts are geared towards addressing various medical needs through innovation and the efficient production of reliable pharmaceutical products. The company's API portfolio is particularly noteworthy, encompassing a range of therapeutic categories that address critical health concerns. These APIs are designed to treat a spectrum of conditions, including autoimmune disorders requiring immunosuppression, mental health challenges addressed by anti-psychotics, and cardiovascular ailments alleviated by anti-anginals. Furthermore, they produce APIs for combating parasitic infections with anthelmintics, managing neurological conditions with anti-convulsants, and easing muscular discomfort with anti-spasmodics. This broad spectrum of API production reflects RPG Life Sciences' dedication to supplying the pharmaceutical industry with the essential components needed to manufacture a diverse range of medications. Beyond APIs, RPG Life Sciences is also a significant player in the generics market, particularly in the realm of immunosuppressant therapy. These generic alternatives provide cost-effective treatment options for patients requiring long-term immunosuppression, often critical after organ transplantation or for managing autoimmune diseases. In addition, the company develops and distributes finished dosage formulations designed for direct patient use. These formulations cover a range of therapeutic areas, underscoring the company's commitment to providing comprehensive pharmaceutical solutions. RPG Life Sciences aims to enhance the quality of life for patients worldwide through its dedication to pharmaceutical innovation and accessibility.

Company Details

Symbol:RPGLIFE
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Ashok Nair
MD & Additional Director
Mr. Amol Narayan Lone
Chief Financial Officer
Mr. Rajesh Shirambekar
Head of Legal, Compliance Officer & Company Secretary

Corporate Events

Recent
Ex-Dividend Date

RPGLIFE Share Price: Frequently Asked Questions

What is the current share price of RPG Life Sciences Ltd?

RPG Life Sciences Ltd (RPGLIFE) trades at ₹2302.00 on NSE and BSE. Market cap ₹3.68K (Cr). Educational data only.

What is the P/E ratio of RPG Life Sciences Ltd?

RPG Life Sciences Ltd has a P/E of 33.04x vs industry average 31.77x.

What is the Bull Run score for RPG Life Sciences Ltd?

RPG Life Sciences Ltd has a Bull Run score of 62/100 based on 25+ financial parameters.

Does RPG Life Sciences Ltd pay dividends?

RPG Life Sciences Ltd has a dividend yield of 0.90%. Past dividends don't guarantee future payments.

What is the ROE of RPG Life Sciences Ltd?

RPG Life Sciences Ltd has ROE of 25.53%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of RPG Life Sciences Ltd?

RPG Life Sciences Ltd has debt-to-equity of 0.00.

Is RPG Life Sciences Ltd a good investment?

Bull Run gives RPG Life Sciences Ltd a score of 62/100. This is not investment advice — consult a SEBI-registered advisor.